Improved EQ-@D and EQ-@D VAS ( p < @ ) and FACIT-Fatigue ( p < @ ) scores were also observed for golimumab + MTX-treated patients at Week @ , Week @ , and Week @ , and greater proportions of golimumab + MTX-treated patients had clinically meaningful improvements in these measures .